Gray V, et al. - In this retrospective biomarker analysis involving 2,929 and 1,948 patients in the Short Course in Oncology Therapy (SCOT) and COIN/COIN-B trials, respectively, researchers intended to confirm if constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors FPR1, TLR3, and TLR4 could predict oxaliplatin benefit in colorectal cancer. They assessed the links between LOF variants and disease-free survival (DFS) and overall survival (OS) using Cox regression, adjusted for confounders, and using additive, dominant, and recessive genetic models. There was no demonstrated a link between any SNP and DFS in the SCOT cohort, or with OS in either cohort, regardless of the type of model used. Overall, constitutional LOF SNPs in FPR1, TLR3, or TLR4 were found to have no relation to differential benefit from oxaliplatin in this prespecified analysis of two large clinical trials. Clinical utility of these SNPs as biomarkers was suggested to be unlikely.